Kilambi News
Tuesday, November 17, 2026

Life sciences also notable: Capsida trial follow-up, Helus depression data

Life Sciences Tuesday, November 17, 2026 - Updated Nov 17, 2026 07:18

STAT reported follow-up progress after a patient death in Capsida's gene therapy trial, a psychedelic drug from Helus improved depression in a study while raising safety questions, and Flagship Pioneering launched a UK lab venture with 100 million pounds.

Why it matters: Trial safety and new venture formation round out a morning led by the Johnson & Johnson and CG Oncology deals.

Data as of Reporting of November 16 to 17, 2026. Each item is single-sourced to the outlet named in the text; the roundup is graded C accordingly.

Capsida reports progress after gene therapy trial death (single-sourced: STAT). Following the death of a patient in its gene therapy trial for a brain disease, Capsida has reported progress in the follow-up investigation, STAT reported on Tuesday. The update is the company’s first substantive word on the path forward for the program since the death was disclosed.

Helus psychedelic improves depression, with safety questions (single-sourced: STAT). A psychedelic drug from Helus improved depression in a clinical study, STAT reported, while leaving safety questions that will shape the program’s next steps. The readout adds to a crowded field of psychedelic mental health programs working toward pivotal trials.

Flagship launches UK lab venture (single-sourced: Endpoints News). Flagship Pioneering has launched a UK laboratory to build AI-driven biotechnology companies, backed by a 100 million pound investment, Endpoints News reported. The venture extends the Flagship company-creation model, behind Moderna, into the United Kingdom’s life sciences cluster.

Sources

  1. After death in gene therapy trial for a brain disease, progress is reported - STAT - 2026-11-17
  2. Helus' psychedelic drug improved depression in study but faces safety questions - STAT - 2026-11-16
  3. Flagship launches UK lab to build AI-driven biotechs with £100M investment - Endpoints News - 2026-11-16